# Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

> **NCT05615220** · PHASE3 · COMPLETED · sponsor: **Emalex Biosciences Inc.** · enrollment: 216 (actual)

## Conditions studied

- Tourette Disorder

## Interventions

- **DRUG:** Ecopipam Hydrochloride

## Key facts

- **NCT ID:** NCT05615220
- **Lead sponsor:** Emalex Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-31
- **Primary completion:** 2025-01-13
- **Final completion:** 2025-02-04
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05615220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05615220, "Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05615220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*